Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Abstract Background Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can limit drug exposure, which may impact on...

Full description

Bibliographic Details
Main Authors: Wan-Ling Tan, Quan Sing Ng, Cindy Lim, Eng Huat Tan, Chee Keong Toh, Mei-Kim Ang, Ravindran Kanesvaran, Amit Jain, Daniel S. W. Tan, Darren Wan-Teck Lim
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
EGFR mutation NSCLC
Metastatic
Afatinib
Brain metastases
Dose
Online Access:http://link.springer.com/article/10.1186/s12885-018-5110-2

Internet

http://link.springer.com/article/10.1186/s12885-018-5110-2

Similar Items